Results 101 to 110 of about 160,542 (279)
, 2021 We report a patient with advanced bladder cancer in which the primary lesion and metastatic site disappeared following the pembrolizumab therapy rechallenge after radiotherapy for bladder cancer lesion of nonresponse of pembrolizumab first challenge.
Tsutomu Nishiyama +5 more
core +1 more source
Diagnostic Cytopathology, EarlyView.ABSTRACT Introduction Lung adenocarcinoma commonly causes malignant pleural effusion (MPE), a condition with poor prognosis and limited treatment options. Pleural effusion specimens offer a minimally invasive source for diagnosis and molecular testing.
Harpreet Virk +5 more
wiley +1 more source
Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications
Barrier Immunity, EarlyView.A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu +9 more
wiley +1 more source
Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications
Head &Neck, EarlyView.ABSTRACT Background Beyond follicular‐derived thyroid carcinomas, lymphomas, and metastatic disease, there are rare pathologies of the thyroid gland that represent a challenge. We report patients with unusual malignancies that mimic similar aggressive cancers. Methods Retrospective case series.
David Z. Allen +12 more
wiley +1 more source
Head &Neck, EarlyView.ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange +16 more
wiley +1 more source
Background: Keynote 177 was a practice changing study, with pembrolizumab versus dealers’ choice chemotherapy +/- biologic significantly improving progression free survival in patients (pts) with previously untreated deficient mismatch repair (dMMR ...
Caird, Susan +15 more
core +1 more source
Head &Neck, EarlyView.ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
Head &Neck, EarlyView.ABSTRACT Background The benefit of consolidation programmed cell death protein 1 (PD‐1) blockade after chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC) remains unclear. Methods Patients with stages II–IVB NPC were randomized (2:1) to pembrolizumab 200 mg or placebo every 3 weeks for up to 17 cycles after chemoradiotherapy ...
Sang Hoon Chun +11 more
wiley +1 more source
Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.
, 2020 BACKGROUND: As the number of indicated malignancies for which immune checkpoint inhibitor therapy such as pembrolizumab grows the descriptions of associated immune-related adverse events (irAEs) increases as well. On rare occasions immunotherapy can lead
Giri, Anshu +4 more
core
A Case of Pembrolizumab Induced Papillitis With Transverse Myelitis
, 2021 Pembrolizumab is a humanized monoclonal antibody that inhibits programmed cell death-1 (PD-1) pathway resulting in an enhanced immune response. Currently, pembrolizumab is an approved treatment for cutaneous melanoma. Very few patients (
Ragha Chaitanya Sakuru; Merati Melody; Nathan Lambert-Cheatham; Sophia Tessema; Luke Salbert; Lina Nagia
core